GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer
GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
GlaxoSmithKline (GSK) has struck a deal to acquire exclusive rights to develop and commercialise an antibody-drug conjugate (ADC) from Syndivia targeting metastatic castration-resistant prostate cancer.
The agreement is reported to be worth up to £268 million, reflecting GSK's push to broaden its oncology pipeline.
Syndivia, a France-based biotech firm specialising in next-generation ADCs, has shown this candidate delivered enhanced tumour reduction in preclinical studies while maintaining an encouraging safety profile.
GSK noted the therapy addresses a significant unmet need given the limited targeted treatment options for this advanced form of prostate cancer.
Author's summary: GSK acquires rights to Syndivia's ADC asset.
More News
- OpenAI completes for-profit shift, gives Microsoft 27% stake
- Scott Woods band returning for Christmas Hoedown | DrumhellerMail
- Nokia commits to full AI-RAN GPU play on new Nvidia RAN compute platform - The Mobile Network
- Atalanta v AC Milan: Confirmed line-ups as Rossoneri look to end hosts' unbeaten start
- Charlie Kirk’s accused killer allowed to wear street clothes in court
- Kieran McKenna Linked with Celtic Job
- Al Nassr Al-Ittihad Jeddah 28 10 2025 Live Score and Match Summary
- From WNBA Court To Playmate Glam: Check Out Kysre Gondrezick’s Sexiest Photos
- 259 Attacks on Olive Harvesters Since Early October
- Eintracht Frankfurt Borussia Dortmund 28 10 2025 Live Score and Match Summary